Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
0.9685
Oct 28 • 3:59 PM ET Dollar change-0.1815 Percentage change(-15.78%)
Aftermarket Close
0.9701
Aftermarket • 7:52 PM ET Dollar change+0.0016 Percentage change(0.17%)
Oct 28, 8:05 AMGeron to discontinue Phase 3 IMpactMF trial of imetelstat in JAK inhibitor–relapsed/refractory myelofibrosis after DMC says OS endpoint unlikely
Index
RUT
Market Cap
622.24M
Enterprise Value
571.27M
Income
-69.89M
Sales
204.56M
Book/sh
0.34
Cash/sh
0.47
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
258
IPO
Jul 31, 1996
P/E
-
Forward P/E
13.09
PEG
-
P/S
3.04
P/B
2.85
P/C
2.06
P/FCF
-
EV/EBITDA
-
EV/Sales
2.79
Quick Ratio
5.16
Current Ratio
6.92
Debt/Eq
1.15
LT Debt/Eq
1.05
Option/Short
Yes / Yes
EPS (ttm)
-0.10
EPS next Y
0.07
EPS next Q
-0.01
EPS this Y
65.38%
EPS next Y
264.44%
EPS next 5Y
-
EPS past 3/5Y
30.48% 14.78%
Sales past 3/5Y
575.71% 273.49%
EPS Y/Y TTM
21.06%
Sales Y/Y TTM
24.39%
EPS Q/Q
-1.22%
Sales Q/Q
17.22%
Insider Own
1.43%
Insider Trans
0.00%
Inst Own
73.22%
Inst Trans
-0.77%
ROA
-13.01%
ROE
-29.24%
ROIC
-15.58%
Gross Margin
96.45%
Oper. Margin
-18.36%
Profit Margin
-34.17%
SMA20
-17.94%
SMA50
-26.47%
SMA200
-32.24%
Trades
Shs Outstand
642.47M
Shs Float
633.28M
52W High
2.01 -51.82%
52W Low
1.04 -6.87%
Volatility
9.70% 5.45%
ATR (14)
0.08
RSI (14)
25.72
Beta
0.57
Rel Volume
8.17
Avg Volume
10.00M
Volume
81,724,857
Perf Week
-16.51%
Perf Month
-21.90%
Perf Quarter
-27.72%
Perf Half Y
-35.86%
Perf YTD
-26.63%
Perf Year
-24.34%
Perf 3Y
-45.89%
Perf 5Y
-38.31%
Perf 10Y
-50.59%
Prev Close
1.15
Price
0.97
Change %
-15.78%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROBERTSON MICHELLEEVP, CHIEF FINANCIAL OFFICERFeb 18 '26Option Exercise0.0027,500027,500Feb 19 06:10 PM
ROBERTSON MICHELLEEVP, CHIEF FINANCIAL OFFICERFeb 18 '26Sale1.949,85519,11917,645Feb 19 06:10 PM
JAMES ZIEGLEROfficerDec 15 '25Proposed Sale1.3720,00027,400Dec 15 05:33 PM
Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.
CEOMr. Harout Semerjian
EVPMs. Michelle J. Robertson
Executive VP of Research & Development and Chief Medical OfficerDr. Joseph Emile Eid M.D.
Executive VP & Chief Commercial OfficerMr. Ahmed ElNawawi
Senior VP & Chief Technical OfficerMr. Shanthakumar Tyavanagimatt